These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 34185336)

  • 41. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
    Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy.
    Cohen D; Hazut Krauthammer S; Cohen YC; Perry C; Avivi I; Herishanu Y; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3540-3549. PubMed ID: 33966088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.
    Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H
    Front Immunol; 2021; 12():743422. PubMed ID: 34659239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
    Eliakim-Raz N; Leibovici-Weisman Y; Stemmer A; Ness A; Awwad M; Ghantous N; Stemmer SM
    JAMA; 2021 Dec; 326(21):2203-2204. PubMed ID: 34739043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
    Erdoğan AP; Ekinci F; Akçalı S; Göksel G
    J Infect Chemother; 2022 Sep; 28(9):1310-1316. PubMed ID: 35701330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
    Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
    JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies.
    Greenberger LM; Saltzman LA; Senefeld JW; Johnson PW; DeGennaro LJ; Nichols GL
    Cancer Cell; 2021 Oct; 39(10):1297-1299. PubMed ID: 34509182
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
    Chong EA; Kumashie KG; Chong ER; Fabrizio J; Gupta A; Svoboda J; Barta SK; Walsh KM; Napier EB; Lundberg RK; Nasta SD; Gerson JN; Landsburg DJ; Gonzalez J; Gaano A; Weirick ME; McAllister CM; Awofolaju M; John GN; Kammerman SC; Novacek J; Pajarillo R; Lundgreen KA; Tanenbaum N; Gouma S; Drapeau EM; Adamski S; D'Andrea K; Pattekar A; Hicks A; Korte S; Sharma H; Herring S; Williams JC; Hamilton JT; Bates P; Hensley SE; Prak ETL; Greenplate AR; Wherry EJ; Schuster SJ; Ruella M; Vella LA
    J Infect Dis; 2024 Jul; 230(1):15-27. PubMed ID: 39052709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
    Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
    Front Immunol; 2022; 13():899972. PubMed ID: 35693807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review.
    Soetedjo NNM; Iryaningrum MR; Lawrensia S; Permana H
    Diabetes Metab Syndr; 2022 Feb; 16(2):102406. PubMed ID: 35104750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
    Kamboj M
    Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
    [No Abstract]   [Full Text] [Related]  

  • 60. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.